A real-world study shows high indications of efficacy and safety of dacomitinib as a first-line treatment for EGFR-mutant NSCLC, with high response rate and median progression-free survival of 16.7 months, making it a valuable option for...
A real-world study shows high indications of efficacy and safety of dacomitinib as a first-line treatment for EGFR-mutant NSCLC, with high response rate and median progression-free survival of 16.7 months, making it a valuable option for...
A real-world study shows high...